Form 8-K - Current report:
SEC Accession No. 0001104659-24-127997
Filing Date
2024-12-12
Accepted
2024-12-12 16:01:15
Documents
14
Period of Report
2024-12-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2430841d1_8k.htm   iXBRL 8-K 42693
2 EXHIBIT 10.1 tm2430841d1_ex10-1.htm EX-10.1 14538
  Complete submission text file 0001104659-24-127997.txt   237893

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vyne-20241212.xsd EX-101.SCH 3042
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vyne-20241212_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vyne-20241212_pre.xml EX-101.PRE 22377
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2430841d1_8k_htm.xml XML 3683
Mailing Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807
Business Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

EIN.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38356 | Film No.: 241544769
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)